key: cord-0796908-r65bwovg authors: Goldust, Mohamad; Hartmann, Karin; Abdelmaksoud, Ayman; Navarini, Alexander A. title: Utility and risk of dermatologic medications during the COVID‐19 pandemic date: 2020-06-15 journal: Dermatol Ther DOI: 10.1111/dth.13833 sha: 3719c7ee9e21226068b8f3fc03018ac24328b166 doc_id: 796908 cord_uid: r65bwovg In the era of staggering speed in development of the novel coronavirus (CoV) pandemic (COVID‐19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV2), we have reviewed the dermatologists’ tools at hand for their utility (and potential risks) in patients affected by COVID‐19. This review aims to shed light on the anti‐viral and pro‐viral potential of drugs routinely used in dermatology to modulate COVID‐19. The literature search included peer‐reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) from January 1990 to March 2020 and by reference lists of respective articles. Somewhat to our surprise, we have found that several of our drugs widely used in dermatology have antiviral potential. On the other hand, we also frequently use immunosuppressive drugs in our dermatologic patients that potentially pose them at increased risk for COVID‐19. This article is protected by copyright. All rights reserved. The global public health is currently challenged with the volcanic spread of Coronavirus disease 2019 (COVID-19). [1] [2] [3] The entire world is in the grip of the looming threat of this viral infection. [4] [5] [6] The World Health Organization (WHO) declared it a health emergency and a pandemic. 7, 8 In light of the lack of evidence-based treatments for COVID-19, repurposing of available medications, including those used by dermatologists, should be considered. In this review, we have tried to evaluate the medications that are generally used in skin diseases (Table 1) . Complex interplay exists between viral replication and host immune response. Due to lack of specific data, more studies need to assess the risk of immunosuppression in patients with This article is protected by copyright. All rights reserved. Chloroquine (CQ), an anti-malarial and autoimmune disease medication, has been found to fulfill several criteria of a broad-spectrum antiviral drug, including significant inhibition of viral infections that invade cells through the endosome pathway, inhibition of autophagy and interference with virus infection and replication. 9 More specifically, and of great current interest, CQ has been demonstrated to possess strong antiviral effects on SARS, the culprit of the Asian epidemic outbreak in 2003. 10 The mechanism is sophisticated and of potential utility for COVID-19: CQ inhibits virus replication by decreasing terminal glycosylation of angiotensin-converting enzyme 2 (ACE2) receptors on the surface of SARS-CoV-infected Vero E6 cells, thus interfering with the binding of SARS-CoV to ACE2 receptors. These ACE2 receptors not only bind SARS-CoV, but also SARS-CoV2, which causes COVID- 19. 10 In addition to its antiviral activity, CQ has an immune-modulating activity that may synergistically increase its antiviral effect. After oral administration, CQ is quickly distributed in the body, including the lung. A very recent study revealed that CQ, in combination with remdesivir, is highly efficient in the management of COVID-19 infection in vitro. The authors therefore suggested that this drug combination should be further explored in patients suffering from COVID-19. Hence, CQ may be one of the best and cheapest medications to treat and prevent CoV infections. 11 In a study on in vitro antiviral activity of hydroxychloroquine for the management of SARS-CoV2, the authors demonstrated that hydroxychloroquine could be more potent than chloroquine to inhibit SARS-CoV-2 in vitro. 12 This article is protected by copyright. All rights reserved. Steroids were largely used in the outbreaks of SARS-CoV 13 and Middle East respiratory syndrome (MERS)-CoV 14 , and they have been used in patients with SARS-CoV2 as well. 15 Acute respiratory distress syndrome (ARDS) is the main cause of death in COVID-19. Pathophysiology of COVID-19 shows that a release of large amount of pro-inflammatory cytokines and chemokines occurs in patients with severe disease. Although steroid treatment may have a role in suppressing the lung inflammation and improve the patients' situation, a meta-analysis of steroid use in patients with SARS, indicated harm and the current recommendation of WHO is against using steroids for management of severe acute respiratory infection in patients with COVID-19 unless indicated for another reason. 16 Acute psoriasis flares following respiratory virus infections caused by various CoV like CoV-HKU1, CoV-OC43, and CoV-229, have been reported. This complication may require systemic therapy with immunosuppressive potential, including methotrexate (MTX). MTX treatment, however, may be associated with specific MTX-induced pneumonitis (MIP, which occasionally evolves to pulmonary fibrosis with a subsequent increase in mortality rate. 17 MXT should therefore be avoided or only used with caution in patients with respiratory distress symptoms due to viral infections, especially CoV. This article is protected by copyright. All rights reserved. Calcineurin inhibitor cyclosporine A has the capability to block the replication of CoV of all genera. 18, 19 However, its potential clinical application as anti-CoV therapeutic remains limited by its immunosuppressive effects. 20, 21 Pentoxifylline Pentoxifylline (PXT) has a tumor necrosis factor (TNF)-antagonizing and anti-proliferative effect, hence used successfully in the treatment of psoriasis. It is a beneficent alternative therapy for pulmonary symptoms in patients with steroid-dependent sarcoidosis. Both psoriasis and sarcoidosis are more frequent in patients with ACE polymorphism. 22 Being an anti-inflammatory, antiviral, immunomodulatory and bronchodilator compound, PTX has been considered a promising drug in SARS treatment, alone or as adjuvant therapy with other medications. 23 Due to its broad effects, we propose that PXT could theoretically be effective against COVID-19 as well. This group of medications is mostly used in inflammatory skin diseases including acne vulgaris. Doxycycline (DOX) has been found to increase intracellular levels of mitochondrial-specific reactive oxygen species (ROS) in a dose-dependent manner and to decrease production of interferon-β. It has anti-inflammatory effects with inhibitory action on This article is protected by copyright. All rights reserved. metalloproteases and modulating effects of pro-inflammatory cytokines including IL-6, IL-8 and tumor necrosis factor (TNF)-alpha that have major role in SARS-CoV2 inflammation. 24 Although DOX could promote COVID-19, clinical studies confirming this risk are still missing. 25 Sodhi and his colleague stated that tetracycline due to its highly lipophilic characteristics, chelate zinc compounds on matrix metalloproteinases (MMPs). Coronaviruses need MMPs for survival, cell to cell adhesion, cell infiltration, and replication, many of which have zinc as part of their MMP complex. 26 Azithromycin is well established as a potent treatment for skin infections and acne vulgaris. Azithromycin has been shown to be active in vitro against Zika and Ebola viruses. 27, 28 In a recent study, combination of hydroxychloroquine and azithromycin was effective in the early reduction of COVID-19 contagiousness. 29 Ivermectin is an anti-parasitic medication that has become popular for treatment of scabies. 30 It has been shown that ivermectin has broad-spectrum anti-viral activity in vitro and in their study Caly and colleagues stated that it is an inhibitor of the SARS-CoV-2, as well. 31 Patri and colleague hypothesized that combination therapy with HCQ and ivermectin may show a consequential and synergistic action in the treatment of This article is protected by copyright. All rights reserved. Dapsone is an aniline derivative and is the first choice of treatment in chronic inflammatory dermatoses. It is effective in blocking inflammatory storms and, therefore, may be a promising therapeutic option of severe COVID-19 cases. 33 Biologics (Table 2) Lebwohl and colleagues stated that although there is no proven data whether biologics increase the susceptibility of the patients to coronavirus, in a pre-coronavirus state, rate of respiratory infection were comparable to placebo. In addition, we may increase the risk of loss of response if we discontinue biologics when they are reintroduced to the patients. 34 A previous study showed that the risk of severe viral pneumonia, including CoV infection, increased by 2.4 times in patients with a history of eczema, leading to the conclusion that major attention should be paid to infected patients with atopy. 35 Dupilumab is a novel therapeutic option for patients with moderate-to-severe atopic dermatitis. It blocks IL-4/IL13signaling and thereby inhibits receptor signaling downstream the JAK-STAT-pathway. Interestingly, IL-4 and IL-13 can increase the ACE2 receptor in primary human alveolar type II cells. 36 Thus; patients with atopic dermatitis treated with dupilumab and exposed to This article is protected by copyright. All rights reserved. COVID-19 could find this drug as a protective medication. On the other hand, any drug with targets immune mechanisms could be found to has the opposite effect. Patients with eczema being treated with dupilumab should be carefully studied for both positive and negative effects of COVID-19. Increased stimulated TNF-α secretion with increasing age has been demonstrated as a possible explanation for the age-related severity of illness in SARS. TNF-α inhibition was Increased expression of numerous cytokines, containing IL-12/23p40, within the brain following either lethal or non-lethal CoV-induced acute encephalomyelitis, indicates that IL-12 expression may affect the generation of interferon (IFN) gamma-secreting T cells. 38 Though, therapeutic strategies designed to inhibit IL-12 and/or IL-23 failed to show significantly impairment of the generation of functional virus-specific T cells. 39 Proinflammatory cytokines related to the IL-17 pathways have been reported to be induced by respiratory viruses such as SARS-CoV. 40 Whether modulation of the IL-17 inflammatory This article is protected by copyright. All rights reserved. pathway or IL-17A-related gene expression might be a potential treatment option for other CoV such as SARS-CoV2 is still a matter for further research. Imatinib is used in dermatology for the treatment of various skin diseases e.g. dermatofibrosarcoma protuberans, melanoma, mastocytosis and graft-versus-host disease. It has been stated that the imatinib target, Abelson tyrosine-protein kinase 2 (Abl2), is needed for efficient SARS-CoV and MERS-CoV replication. Imatinib could theoretically be effective against COVID- 19. 41 No clinical evidence of effectiveness has been published. In the setting of a catastrophic viral pandemic, a careful examination of the dermatology toolbox is in order. In our opinion, it might be prudent to wait until after the threat of This article is protected by copyright. All rights reserved. -None known -None known S.C. -None known -Inhibits potential target of SARS-CoV -Weigh the risk vs. benefits of the use of biologic medication on a case-by-case basis. * The benefit-to-risk ratio of any immunosuppressive therapeutic intervention should be carefully weighed in patients with comorbidities on a case-tocase basis. *Patients at risk of complications: >60 years old), those with serious chronic medical conditions e.g. cardiovascular disease, diabetes, severe hypertension, liver disease, kidney disease, respiratory system compromise, internal malignancies or tobacco use, among others. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) Solidarity and transparency against the COVID-19 pandemic Priorities for global health community in COVID-19 pandemic The effect of quarantine and isolation for COVID-19 in general population and dermatologic treatments In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) SARS: systematic review of treatment effects Corticosteroid therapy for critically ill patients with middle east respiratory syndrome Clinical features of patients infected with 2019 novel coronavirus in Wuhan On the use of corticosteroids for 2019-nCoV pneumonia Methotrexate-induced pneumonia: A dermatologist wake up call Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to sarcoidosis: A metaanalysis Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic Psoriasis and pentoxifylline: a clinical, histopathologic, and immunohistochemical evaluation Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered Anti-inflammatory properties of low and high doxycycline doses: an in vitro study Doxycycline Induces Mitophagy and Suppresses Production of Interferon-β in IPEC-J2 Cells. Front Cell Infect Microbiol Therapeutic Potential for Tetracyclines in the Treatment of COVID-19 Zika virus cell tropism in the developing human brain and inhibition by azithromycin Evaluation of Ebola Virus Inhibitors for Drug Repurposing Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study The efficacy of topical and oral ivermectin in the treatment of human scabies Dapsone in dermatology and beyond This article is protected by copyright. All rights reserved The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment? Should biologics for psoriasis be interrupted in the era of COVID-19? Does atopy affect the course of viral pneumonia?AllergolImmunopathol (Madr) Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus Tobinick E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection IFN-gamma is required for viral clearance from central nervous system oligodendroglia Generation of a protective T-cell response following coronavirus infection of the central nervous system is not dependent on IL-12/23 signaling